CD20: a target antigen for immunotherapy of autoimmune diseases

Federico Perosa; Elvira Favoino; Maria Antonietta Caragnano; Marcella Prete; Franco Dammacco

doi:10.1016/j.autrev.2005.04.004

CD20: a target antigen for immunotherapy of autoimmune diseases

Autoimmun Rev. 2005 Nov;4(8):526-31. doi: 10.1016/j.autrev.2005.04.004.

Authors

Federico Perosa¹, Elvira Favoino, Maria Antonietta Caragnano, Marcella Prete, Franco Dammacco

Affiliation

¹ Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy. [email protected]

PMID: 16214090
DOI: 10.1016/j.autrev.2005.04.004

Abstract

This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases. A peptide that mimics the CD20 epitope recognized by Rituximab is employed to stimulate the host immune response against CD20.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Antigens, CD20 / drug effects
Antigens, CD20 / immunology*
Autoimmune Diseases / immunology
Autoimmune Diseases / therapy*
Humans
Immunotherapy

Substances

Antibodies, Monoclonal
Antigens, CD20